TURINABOL (CHLORODEHYDROMETHYLTESTOSTERONE)
Description
Chlorodehydromethyltestosterone, the generic name for the more recognized brand Oral Turinabol, is a potent derivative of Dianabol. This oral steroid is structurally a cross between methandrostenolone and clostebol (4-chlorotestosterone), having the same base structure as Dianabol with the added 4-chloro alteration of clostebol. This alteration makes chlorodehydromethyltestosterone a milder cousin of Dianabol, the new steroid displaying no estrogenic and a much less androgenic activity in comparison to its more famous counterpart. The anabolic activity of chlorodehydromethyltestosterone is somewhat lower than that of Dianabol as well, but it does maintain a much more favorable balance of anabolic to androgenic effect. This means that at any given level of muscle-building activity, chlorodehydromethyltestosterone will be less likely to produce androgenic side effects.
Oral Turinabol became a steroid of infamy during the 1990s, when it was revealed that the drug had been one of the closely held secrets inside the “East German Doping Machine.” This is referring to the state-sponsored doping program, called “State Plan Research Theme 14.25,” that operated in East Germany between 1974 and 1989. It was an aggressive anabolic steroid administration program, designed with one goal in mind: cheating the Olympic drug test. In many cases, the Olympic athletes, both male and female, were unwitting participants, simply told by their trainers and coaches that they were being given “vitamins.” Many of these blue vitamins turned out to be Oral Turinabol, a potent and undetectable (at the time) anabolic steroid. As many as 10,000 athletes were given anabolic steroids during the time the program was active, many of them taking Oral Turinabol.
How Supplied
Chlorodehydromethyltestosterone is typically supplied in one-milligram and five-milligram tablets.
Effective Dosages
When used by men for physique- or performance-enhancing purposes, this drug is commonly used in the range of 15-40 milligrams per day, taken in cycles lasting no more than six to eight weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in lean muscle mass and strength. This agent is most often applied as a pre-contest or cutting steroid for bodybuilding purposes, and is not viewed as an ideal bulking agent due to its lack of estrogenicity. Women commonly use five milligrams per day, which is taken in cycles lasting no more than four to six weeks. Virilizing effects are unlikely at this level of use, though cannot be excluded. Much higher doses were often used with female athletes in the former GDR doping program, but often to detriment of strong virilizing side effects.
Side Effects
Estrogenic: Chlorodehydromethyltestosterone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.
Androgenic: Although chlorodehydromethyltestosterone is classified as an anabolic steroid, androgenic side effects are still possible with this substance. These may include bouts of oily skin, acne and body/facial hair growth. Doses higher than normally prescribed are more likely to cause such side effects. Anabolic-androgenic steroids (AAS) may also aggravate male-pattern hair loss. Women are additionally warned of the potential virilizing effects of AAS. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth and clitoral enlargement.
Liver Toxicity:Chlorodehydromethyltestosterone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated AAS can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances, life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to six to eight weeks, in an effort to avoid escalating liver strain.
Cardiovascular: Anabolic-androgenic steroids can have deleterious effects on serum cholesterol, increasing the risk of arteriosclerosis. They may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction. Chlorodehydromethyltestosterone has a strong effect on the hepatic management of cholesterol due to its non-aromatizable nature, structural resistance to liver breakdown and route of administration. People with high cholesterol or a familial history of heart disease should be especially careful when considering AAS abuse. To help reduce cardiovascular strain, it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol and simple carbohydrates at all times during active AAS administration.
Testosterone Suppression: All AAS, when taken in doses sufficient to promote muscle gain, are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within one to four months of drug cessation. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
The above side effects are not inclusive.
Oral Turinabol has been unavailable as a prescription drug product in Germany (the sole country of manufacture for most of its history) since 1994. A very small number of pharmaceutical companies have marketed the drug since, mainly in less regulated markets of Eastern Europe and Asia, where black-market demand still influences production.
References:
Doerner G and Schubert A. Proc Intern Congr Hormonal Steroids; Milan 1962, Excerpta Med Intern Congr Ser No. 51, 210.
Schwarz S, Onken D and Schubert A. The Steroid Story of Jenapharm: From the Late 1940s to the Early 1970s. Steroids, Volume 64; Issue 7, July 1999, Pages 439-445.
William Llewellyn
Description
Chlorodehydromethyltestosterone, the generic name for the more recognized brand Oral Turinabol, is a potent derivative of Dianabol. This oral steroid is structurally a cross between methandrostenolone and clostebol (4-chlorotestosterone), having the same base structure as Dianabol with the added 4-chloro alteration of clostebol. This alteration makes chlorodehydromethyltestosterone a milder cousin of Dianabol, the new steroid displaying no estrogenic and a much less androgenic activity in comparison to its more famous counterpart. The anabolic activity of chlorodehydromethyltestosterone is somewhat lower than that of Dianabol as well, but it does maintain a much more favorable balance of anabolic to androgenic effect. This means that at any given level of muscle-building activity, chlorodehydromethyltestosterone will be less likely to produce androgenic side effects.
Oral Turinabol became a steroid of infamy during the 1990s, when it was revealed that the drug had been one of the closely held secrets inside the “East German Doping Machine.” This is referring to the state-sponsored doping program, called “State Plan Research Theme 14.25,” that operated in East Germany between 1974 and 1989. It was an aggressive anabolic steroid administration program, designed with one goal in mind: cheating the Olympic drug test. In many cases, the Olympic athletes, both male and female, were unwitting participants, simply told by their trainers and coaches that they were being given “vitamins.” Many of these blue vitamins turned out to be Oral Turinabol, a potent and undetectable (at the time) anabolic steroid. As many as 10,000 athletes were given anabolic steroids during the time the program was active, many of them taking Oral Turinabol.
How Supplied
Chlorodehydromethyltestosterone is typically supplied in one-milligram and five-milligram tablets.
Effective Dosages
When used by men for physique- or performance-enhancing purposes, this drug is commonly used in the range of 15-40 milligrams per day, taken in cycles lasting no more than six to eight weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in lean muscle mass and strength. This agent is most often applied as a pre-contest or cutting steroid for bodybuilding purposes, and is not viewed as an ideal bulking agent due to its lack of estrogenicity. Women commonly use five milligrams per day, which is taken in cycles lasting no more than four to six weeks. Virilizing effects are unlikely at this level of use, though cannot be excluded. Much higher doses were often used with female athletes in the former GDR doping program, but often to detriment of strong virilizing side effects.
Side Effects
Estrogenic: Chlorodehydromethyltestosterone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.
Androgenic: Although chlorodehydromethyltestosterone is classified as an anabolic steroid, androgenic side effects are still possible with this substance. These may include bouts of oily skin, acne and body/facial hair growth. Doses higher than normally prescribed are more likely to cause such side effects. Anabolic-androgenic steroids (AAS) may also aggravate male-pattern hair loss. Women are additionally warned of the potential virilizing effects of AAS. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth and clitoral enlargement.
Cardiovascular: Anabolic-androgenic steroids can have deleterious effects on serum cholesterol, increasing the risk of arteriosclerosis. They may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction. Chlorodehydromethyltestosterone has a strong effect on the hepatic management of cholesterol due to its non-aromatizable nature, structural resistance to liver breakdown and route of administration. People with high cholesterol or a familial history of heart disease should be especially careful when considering AAS abuse. To help reduce cardiovascular strain, it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol and simple carbohydrates at all times during active AAS administration.
Testosterone Suppression: All AAS, when taken in doses sufficient to promote muscle gain, are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within one to four months of drug cessation. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
The above side effects are not inclusive.
AvailabilityOral Turinabol has been unavailable as a prescription drug product in Germany (the sole country of manufacture for most of its history) since 1994. A very small number of pharmaceutical companies have marketed the drug since, mainly in less regulated markets of Eastern Europe and Asia, where black-market demand still influences production.
References:
Doerner G and Schubert A. Proc Intern Congr Hormonal Steroids; Milan 1962, Excerpta Med Intern Congr Ser No. 51, 210.
Schwarz S, Onken D and Schubert A. The Steroid Story of Jenapharm: From the Late 1940s to the Early 1970s. Steroids, Volume 64; Issue 7, July 1999, Pages 439-445.
William Llewellyn
Last edited:
